hansen medical

Patients

A New Robotic Approach in the Treatment of Vascular Disease

At Hansen Medical, we know that patients are more involved than ever in partnering with their physicians  to understand the choices that are available for the diagnosis and treatment of their health conditions. We know that patients who have symptoms such as pain with walking (claudication), non-healing leg sores (leg ulcers), poor blood circulation, and enlarged blood vessels (aneurysms) have choices to improve their symptoms and quality of life. There are robotic minimally invasive approaches to many peripheral vascular interventions to treat vascular disease.  As we continue to develop new solutions for vascular disease, we invite you to return to see what new choices may be available to consider discussing in the next appointment with your physician.

Our technology offers a new robotic approach to the treatment of vascular disease.

Peripheral vascular disease affects more than 27 million patients worldwide¹. Patients with peripheral vascular disease can suffer from decreased blood flow which can lead to disability and amputation, stroke or blood clots, and death. Approximately 500,000 patients are treated for their symptoms of pain, or to save their legs each year in the European Union². The rates of diabetes, hypertension, atherosclerosis, and obesity are also on the rise worldwide and are contributors to the growth rate of vascular disease in an aging population^3,4.

We have led the development of robotic catheter technology to provide physicians with a new approach for the management of vascular disease.  Our technology has the following potential benefits:

• Less blood vessel injury than moving catheters by hand⁵.
• May shorten procedure time⁶.
• Potential for less patient exposure to x ray and use of contrast dye.
• Potential to avoid open surgery by using less invasive treatment options.

If you have vascular disease, talk to your doctor about whether a robotic catheter procedure is an option for you.

At Hansen Medical, we are passionate about creating robotic solutions that provide physicians with a better suite of tools for their procedural and therapeutic success. We believe that better tools will lead to better outcomes and care for vascular patients.

For more information on vascular disease and treatment options:

• VascularWeb
• American Stroke Association
• ESVS
• American Heart Association
• Cardiovascular Disease Foundation
• Center for Disease Control and Prevention

Hansen Medical may provide links to third party web sites as a convenience to the users of this website. Hansen Medical does not endorse, warrant, or verify the accuracy, reliability, completeness, or timeliness of such third party websites and is not responsible for their content. In particular, the information practices of those third parties and websites are outside of our control and are not covered by our Legal Terms.

The material on this web site is provided to educate patients about Hansen Medical, Inc. and our products and services. The information provided on the web site is for general information only, and is designed to support, not replace, the relationship that exists between you and your physician. Hansen Medical Inc. does not provide medical services or advice as part of this web site and the information contained on this web site is not intended to be used for medical diagnosis or treatment. Please consult your physician with any questions you have about your symptoms, diagnosis and treatment.

 

¹Discovery London and TASC II 2008. The Worldwide Burden of Peripheral Artery Disease - Intersociety Consensus for Management of PAD.  www.tasc-2-pad.org/upload/SSRubriqueProduit/Fichier2/961.pdf.  p. 4
pg.4: "It is estimated that 27 million individuals in Europe and North America have PAD"

²Millennium Research Group. European markets for peripheral vascular devices, 2008.

³Hypertension and Diabetes.  Fisman EZ, Tenenbaum A (eds): Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets. Adv Cardiol. Basel, Karger, 2008, vol 45, pp 82–106.
p. 83: “Between 1976 and 1988, the prevalence of diabetes (among people age 40–74 years) rose from 11.4 to 14.3% in the USA [7]. Similar increase in the prevalence of diabetes has been described in other parts of the world [8–10]. It is estimated that globally, the number of people with diabetes will rise from 151 millions in the year 2000 to 221 million by the year 2010 and to 300 million by 2025 [11]. The projections of increasing numbers of people with diabetes are driven mainly by the anticipated world population growth, especially amongst the middle-aged and elderly. This spectacular increase in the frequency of type 2 Grossman/Messerli 84 diabetes is being paralleled by a similar alarming increase in obesity [12] which is the major risk factor for type 2 diabetes. Type 2 diabetes is a descriptive term and a manifestation of a much broader underlying disorder. This combination of risk factors is partly responsible for the increased risk of cardiovascular disease in diabetes [16]. The prevalence of hypertension is expected to increase in the next 25 years from 26.5% in the year 2000 to 29.2% in the year 2025 [17]. The incidence of hypertension in patients with type 2 diabetes is approximately twofold higher than in age-matched subjects without the disease [18]. 

⁴Discovery London and TASC II 2008. The Worldwide Burden of Peripheral Artery Disease - Intersociety Consensus for Management of PAD.  www.tasc-2-pad.org/upload/SSRubriqueProduit/Fichier2/961.pdf.  p. 4

⁵Bismuth J,  Kashef E, Cheshire N, Lumsden A. Feasibility and Safety of Remote Endovascular Catheter Navigation in a Porcine Model. J Endovasc Ther  2011;18:243–249.
p.248: “The present study indicates that vessel wall damage can be reduced, despite currently being able to navigate in only 2-dimensional imaging.”
p.248: “Due to its stability, the Hansen vascular catheter moves purposefully through the vessel, thus reducing the damage it causes, as reflected in the less significant intimal thrombus and surface disruption in the robotic cases versus the manual control.”

⁶Riga CV, Cheshire NJ, Hamady MS, Bicknell CD.  The role of robotic endovascular catheters in fenestrated stent grafting. J Vasc Surg. 2010 Apr;51(4):810-820.
p. 819: Results: Median procedure time for cannulation of all four vessels was reduced using the robotic system (2.87 min, interquartile range [IQR; 2.20-3.90] versus 17.24 min [11.90-19.80]; P < .001) for each individual operator, regardless of the level of endovascular experience. The total number of wire/catheter movements taken to complete the task was also significantly reduced (38, IQR [29-57] versus 454 [283-687]; P < .001). There were significant differences in time and movement for cannulation of each individual vessel in the phantom. Robotic catheter operator radiation exposure was negligible as the robotic workstation is remote and away from the radiation source. Overall performance scores significantly improved using the robotic system, despite minimal operator exposure to this technology (IC3ST score 29/35, IQR [22.8-30.7] versus 19/35 [13-24.3]; P  .002). Each group of operators demonstrated an improvement in performance with robotic cannulation. For group A, median IC3ST score was 28/35, IQR (22-33) versus 15/35 (11-20); P  .04; for group B, 30/35 (27-31) versus 19/35 (18-24); P  .07; and for group C, 28.8/35 (28.5-29) versus 22/35 (16-24); P  .06. For groups B and C, these differences did not reach statistical significance.Conclusion: Robotic catheterization of target vessels during this procedure is feasible and minimizes radiation exposure for the operator. Steerable robotic catheters with intuitive control may overcome some of the limitations of standard catheter technology, enhance target vessel cannulation, reduce instrumentation, and improve overall performance scores.